Smith Asset Management Group LP decreased its position in Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 0.4% during the second quarter, Holdings Channel reports. The firm owned 26,890 shares of the biopharmaceutical company’s stock after selling 100 shares during the period. Smith Asset Management Group LP’s holdings in Achillion Pharmaceuticals were worth $210,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently made changes to their positions in ACHN. Schonfeld Strategic Advisors LLC purchased a new position in shares of Achillion Pharmaceuticals during the first quarter worth $101,000. Fox Run Management L.L.C. purchased a new position in shares of Achillion Pharmaceuticals during the second quarter worth $105,000. Legal & General Group Plc raised its position in shares of Achillion Pharmaceuticals by 15.7% in the first quarter. Legal & General Group Plc now owns 18,010 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 2,443 shares during the period. HBK Investments L P purchased a new position in shares of Achillion Pharmaceuticals during the first quarter worth $455,000. Finally, Royal Bank of Canada raised its position in shares of Achillion Pharmaceuticals by 29.3% in the first quarter. Royal Bank of Canada now owns 64,385 shares of the biopharmaceutical company’s stock worth $497,000 after buying an additional 14,584 shares during the period. Institutional investors own 79.43% of the company’s stock.
Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) traded up 0.48% on Wednesday, hitting $8.29. The stock had a trading volume of 1,457,683 shares. The company has a market capitalization of $1.13 billion, a PE ratio of 169.18 and a beta of 2.21. The firm has a 50-day moving average of $8.42 and a 200 day moving average of $8.44. Achillion Pharmaceuticals Inc. has a 1-year low of $5.57 and a 1-year high of $10.95.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. During the same quarter in the previous year, the business earned ($0.25) earnings per share. On average, equities analysts anticipate that Achillion Pharmaceuticals Inc. will post ($0.61) earnings per share for the current fiscal year.
A number of brokerages have recently weighed in on ACHN. Leerink Swann reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research note on Sunday, June 12th. Chardan Capital increased their price target on Achillion Pharmaceuticals from $4.00 to $5.00 and gave the stock a “sell” rating in a research report on Friday, September 23rd. Jefferies Group reissued a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Monday. FBR & Co started coverage on Achillion Pharmaceuticals in a research report on Thursday, September 15th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, Robert W. Baird reissued an “outperform” rating and set a $10.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $10.70.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.